文献速递中枢神经肿瘤放疗放疗物理与技术

大分割质子再程放疗治疗复发胶质母细胞瘤的单机构大样本临床与剂量学结果

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single-Institution Series.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-07-02

回顾性分析89例复发胶质母细胞瘤患者接受35 Gy/10次大分割质子再程放疗,中位随访7.2个月,再程放疗后中位总生存8.3个月(95%CI 6.27-9.47),6个月和12个月OS分别为62.6%和24.9%。复合剂量学显示初程放疗贡献大部分危及器官累积剂量,质子再程追加暴露有限;3-4级放射性坏死发生率5.8%,无>4级毒性。与49例光子再程放疗对比总生存无差异。

要点

  • 质子再程放疗35 Gy/10次可行,3-4级放射性坏死率5.8%。
  • 再程放疗后中位OS 8.3个月,6/12个月OS为62.6%/24.9%。
  • 复合剂量学显示质子再程对危及器官累积剂量贡献有限。

核心结论

  • 大分割质子再程放疗治疗复发胶质母细胞瘤可行且毒性结果良好,可作为再治疗选择,但需前瞻性研究明确最佳患者选择。

研究设计与样本

  • 单机构回顾性研究,纳入2015至2025年89例复发胶质母细胞瘤接受35 Gy/10次大分割质子再程放疗的患者,中位随访7.2个月。
  • 另设49例同期接受大分割光子再程放疗的对比队列,采用Kaplan-Meier法估计总生存,Cox比例风险模型分析相关因素。

主要发现

  • 质子队列再程放疗后中位OS为8.3个月(95%CI 6.27-9.47),6个月和12个月OS分别为62.6%和24.9%。
  • 多因素分析显示年龄增加与更差OS独立相关。
  • 质子与光子再程放疗队列的OS无差异。
  • 8例(5.8%)发生3级或4级放射性坏死,未观察到>4级毒性。
  • 复合剂量学(α/β=2等效剂量)显示初程放疗占危及器官累积剂量的大部分,质子再程追加暴露有限。

关键数值与推荐

  • 再程放疗方案为35 Gy分10次大分割照射。
  • 复合剂量学采用2 Gy分次等效剂量(α/β=2)计算危及器官累积剂量。
  • 毒性分级中3级或4级放射性坏死共8例(5.8%),无>4级毒性。

临床怎么用

  • 对于复发胶质母细胞瘤,可考虑大分割质子再程放疗35 Gy/10次作为再治疗选项。
  • 制定再程放疗计划时应评估初程放疗对危及器官累积剂量的贡献,质子再程追加暴露有限。
  • 年龄增加与更差OS相关,患者选择需综合考虑年龄等因素。

局限性

  • 回顾性单机构研究设计。
  • 中位随访时间7.2个月。
  • 需前瞻性研究进一步明确最佳患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Management of recurrent glioblastoma remains a major challenge, with no treatment shown to meaningfully prolong survival. Reirradiation may offer local control but is often constrained by concerns regarding dose to critical normal tissues. We evaluated clinical outcomes, toxicity, and cumulative dosimetric parameters in patients with recurrent glioblastoma treated with hypofractionated proton reirradiation. METHODS AND MATERIALS: We retrospectively identified patients with recurrent glioblastoma treated with hypofractionated reirradiation courses of 35 Gy in 10 fractions. Cumulative composite dosimetry was calculated using 2 Gy per fraction equivalent dose (α/β = 2) for organs at risk. Overall survival (OS) was estimated using Kaplan-Meier methods. Cox proportional hazards modeling was performed to identify factors associated with OS. A contemporaneous cohort treated with hypofractionated photon reirradiation was identified for comparison. RESULTS: A total of 89 patients were treated with hypofractionated proton reirradiation for recurrent glioblastoma between 2015 and 2025, with a median follow-up of 7.2 months. Median age was 58 years (IQR, 48-68), and 48% underwent re-resection before reirradiation. Composite dosimetry demonstrated that the initial radiation course accounted for the majority of cumulative organs at risk dose, with proton reirradiation contributing limited additional exposure. Median OS from reirradiation in the proton cohort was 8.3 months (95% CI, 6.27-9.47), with 6- and 12-month OS of 62.6% and 24.9%, respectively. On multivariable analysis, increasing age was independently associated with worse OS. A comparator cohort of 49 patients treated with photon reirradiation was identified. OS did not differ between proton and photon reirradiation cohorts. Eight (5.8%) patients experienced grade 3 or 4 radiation necrosis. No grade >4 toxicities were observed. CONCLUSIONS: Hypofractionated proton reirradiation was feasible and associated with favorable toxicity outcomes, supporting its use as a retreatment option. Prospective studies are needed to further define optimal patient selection.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Linkowski L, Messing I, Berger M, et al. Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single-Institution Series. Int J Radiat Oncol Biol Phys. 2026. PMID: 42392324. doi:10.1016/j.ijrobp.2026.06.3058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。